49° and Partly Cloudy
Image
Sanofi is collaborating with two other insulin manufacturers to offer price caps or savings programs, lowering the cost of the drugs to $35. The moves took effect on January 1, 2024.
Approximately 8.4 million Americans depend on insulin to survive, and now there is a cap on the out-of-pocket cost.
Other good news is Civica Rx, a non-profit generic drug company, is working on formulating and selling insulin for no more than $30 a vial.
